Form D · Biotechnology
Santa Maria Biotherapeutics, Inc.
Brisbane, CA · CIK 0001593628
Offering snapshot reported Jan 13, 2014 · SEC filing
- Reported sold
- $6.31M Offering amount: $6.31M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 9, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 13, 2014 | Initial | $6,311,156 | No comparison | 10 | SEC filing |
| Dec 10, 2013 | Initial | $17,998,555 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-209863
Source: Form D, filed Jan 13, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Isaac Ciechanover | Director, Executive |
| Carol Gallagher | Director |
| Christopher Haqq | Executive |
| Joel Marcus | Director |
| John F. Mc Grath | Executive |
| Beth Seidenberg | Director |
| Gad Soffer | Executive |
| Eckard Weber | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3260 Bayshore Blvd.
Brisbane, CA, 94005
Brisbane, CA, 94005